FDA approves first orexin receptor agonist for narcolepsy
Start here
Takeda's Orzeyful (oveporexton) has become the first orexin receptor agonist approved by the FDA for narcolepsy, opening a new drug class rooted in the independent discovery of orexin in the 1990s by teams at Scripps and UT Southwestern. Many researchers believe the class could follow the trajectory of GLP-1 drugs, expanding from its initial indication into a much broader range of uses. Analysts forecast the global narcolepsy drug market will exceed $6.4 billion by 2031. Questions still open include which indications beyond sleep disorders the class might reach, and whether it can replicate the commercial success of GLP-1 therapies.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- NaturePickWill this sleep-disorder drug be the next big blockbuster?
Takeda's Orzeyful (oveporexton) became the first orexin receptor agonist approved by the FDA for narcolepsy, and multiple researchers think the class could expand beyond sleep disorders much as GLP-1 drugs did. The article traces orexin's independent discovery in the 1990s by teams at Scripps and UT Southwestern, and cites analysts projecting the global narcolepsy drug market to exceed $6.4 billion by 2031.
Coverage and heat for this story
Reports so far 1·Heat now 11·Peak heat 17 (Oct 20 08:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.